Get The Free Sample Complete
SWOT & PESTLE Analysis Report
This report is shared in order to give you an idea of what the complete SWOT & PESTLE analysis report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals. We also guarantee that you cannot find matched quality at such competitive and economic pricing.
Get Your Free Summary Copy of the
SWOT & PESTLE Analysis Report
Get the summary SWOT & PESTLE.com report delivered straight to your email inbox for free.
Our insightful and holistic reports have helped corporate,academia and researchers to take their research forward. Like us on Facebook to stay updated with the latest published SWOT & PESTLE Report.

Abbott Laboratories SWOT & PESTLE Analysis

ID : 52612553| Jan 2020| 15 pages

COMPANY PROFILE -Abbott Laboratories

Business Sector :Healthcare

Operating Geography :USA, North America, Global

About Abbott Laboratories :

Abbott Laboratories is an American company founded by Dr. Wallace C. Abbott. The company was among the pioneers of the scientific practice of pharmacy. The company has a tradition of helping people worldwide live a healthy life. Abbott is present in more than 160 countries and employs 103,000 people. The company has products in Cardiovascular, Diabetes, Diagnostics, Neuromodulation, Nutrition and Pharmaceuticals. It has been one of Fortune’s most admired companies since 1984, and number 1 in medical products from 2014-2019. Abbot Laboratories Mission is to “building life-changing technologies that keep heart healthy, nourish the body at every stage of life, help one feel and move better, and bring one information, medicines and breakthroughs to manage their health.”

Abbott Laboratories Revenue :


$30,578 million – FY ending 31st Dec 2018 (11.6% increase YoY)
$27,390 million – FY ending 31st Dec 2017

Competitive Analysis of Abbott Laboratories

SWOT
PESTLE
The SWOT analysis of Abbott Laboratories is presented below:
Strengths
Weaknesses
1. Strong focus on high potential fields
2. Broad geographic reach spanning 160 countries
3. Operating systems designed for success
4. Market leadership in multiple fields
5. Strong performance by all four major business segments
1. Controversies affecting the brand image
Opportunities
Threats
1. Growing market for personalized medicines
2. Rising demand for clinical diagnostics driven by infectious and chronic diseases
1. Risks associated with mergers and acquisitions
2. Rising use of technology in healthcare has led to increased vulnerability to cyber-attacks
3. Government regulations regarding drug pricing controls
SWOT & PESTLE (combined)
Complete Report
USD 12.53
*
  • with PayPal
  • with Debit/Credit card
Great quality, Affordable pricing.
Safe and secure payments

Detailed SWOT Analysis of Abbott Laboratories

 

Strength

This section is available only in the 'Complete Report' on purchase.

Weakness

This section is available only in the 'Complete Report' on purchase.

Opportunity

This section is available only in the 'Complete Report' on purchase.

Threat

1. Risks associated with mergers and acquisitions: A key part of Abbott’s growth and competitive strategy is mergers and acquisitions. But these deals are fraught with a lot of risks. Abbott has been affected by many regulatory and legal issues during previous deals. Many of these were not directly Abbott’s fault. In 2016, the acquisition process of St. Jude Medical faced hurdles when St. Jude faced accusations that its heart monitoring equipment is prone to hacking. Already, Abbott was dealing with problems regarding acquisition of another company Alere, whose business was undergoing probes for accounting issues. In 2015, Abbott had acquired Mylan. But in 2016, the value of the Mylan stake fell due to uproar against the increase in price of the Epipen allergy shot. Though they we were not completely Abbott’s fault, to some extent it was the Abbott CEO’s decisions that led to these situations. Mylan was having issues earlier too, in its failed acquisition attempt of Perrigo and aggressively resisting a takeover from Teva. Though most of Alere’s problems came out in the open only after the deal with Abbott was done, Abbott was aware of one government investigation, which should have been a warning sign.

2. Rising use of technology in healthcare has led to increased vulnerability to cyber-attacks: Healthcare sector is increasingly using technology to provide better care for patients. However, the rising use of technology brings with it the threat of cyber-attacks. Hackers can implant malicious software in medical devices at the distribution center in the supply chain, from where the devices are sent to various hospitals and patients who use them are at risk. Hackers can also disrupt hospital operations by hacking into IoT-enabled water systems and HVAC systems. Abbott has also been affected by cyber security concerns in the past. In 2017, 500,000 pacemakers where recalled by the US Food and Drug administration over hacking vulnerabilities. Many of these pacemakers were manufactured by Abbott and sold under St. Jude Medical brand. Abbott had then announced a firmware update to fix the danger.

3. Government regulations regarding drug pricing controls: US drug prices have been found to be higher by as much as four times when compared to the prices in similarly developed countries. Overall medication costs are also significantly more in the US even after subtracting rebates. A proposal presented by House Speaker Nancy Pelosi in 2019 recommends giving the federal government the power to negotiate and set a limit on the price of drugs. All US citizens, and not just Medicare patients, will be positively impacted by this bill. By virtue of this bill, the government will also be able to penalize drug companies who do not follow the price limits. However, lesser profits in the pharma industry will translate to it being less lucrative for investors. The demand for new research and innovative cures will thus be reduced and will directly impact companies such as Abbot.

SWOT & PESTLE (combined)
Complete Report
USD 12.53
*
  • with PayPal
  • with Debit/Credit card
Great quality, Affordable pricing.
Safe and secure payments

Check Out Analysis of Other Relevant Companies

TABLE OF CONTENTS
DELIVERY AND FORMAT
WHY CHOOSE US?
References used in Abbott Laboratories Analysis Report

1. Annual Report 2018 - https://www.abbottinvestor.com/static-files/9f7cf4e4-5ca1-43cf-9034-97cdd1256cf3

2. Abbot Laboratories revenue - https://www.macrotrends.net/stocks/charts/ABT/abbott-laboratories/revenue

3. Secret trove reveals bold ‘crusade’ to make OxyContin a blockbuster - https://www.statnews.com/2016/09/22/abbott-oxycontin-crusade

4. Abbott Laboratories to pay $1.6 billion over misbranding drug - https://edition.cnn.com/2012/05/07/justice/abbott-fine-drug/index.html

The detailed complete set of references are available on request in the 'Complete report' on purchase.

How to Reference This Page?

You can use the following in your reference section in order to give credit to the source. For different referencing styles and detailed guidelines, please click here.

Abbott Laboratories SWOT & PESTLE Analysis - SWOT & PESTLE.COM

SWOT & PESTLE.com (2020). Abbott Laboratories SWOT & PESTLE Analysis - SWOT & PESTLE.com. [online] Available at: https://www.swotandpestle.com/abbott-laboratories/ [Accessed 25 Feb, 2020].

In-text: (SWOT & PESTLE.com, 2020)

Copyrights and Disclaimer

Abbott Laboratories SWOT and PESTLE analysis has been conducted by Nipunn V and reviewed by senior analysts from Barakaat Consulting.

Copyright of Abbott Laboratories SWOT and PESTLE Analysis is the property of Barakaat Consulting. Please refer to the Terms and Conditions and Disclaimer for usage guidelines.

You might also like to check out :
Abbott Laboratories SWOT & PESTLE Analysis
Price : USD 12.53